首页> 外文期刊>Quarterly Journal of Medicine >Steroid resistance in asthma
【24h】

Steroid resistance in asthma

机译:哮喘中的类固醇抵抗

获取原文
获取原文并翻译 | 示例
       

摘要

Resistance to the anti-inflammatory effects of gluco-corticoids in asthma and other inflammatory and immune diseases is uncommon, but presents a management problem. Understanding the mechanisms of steroid resistance provides new insights into the mechanism of steroid action as well as the underlying chronic disease process. In patients with primary steroid-resistant (SR) asthma there is no abnormality in the pharmacokinetics of the exogenous steroid and no significant defect in steroid binding to the glucocorticoid receptor (GR). Recent studies have demonstrated a marked reduction in the binding of GR to DNA; this appears to be due to increased binding of GR to the transcription factor activator protein-1 (AP-1). Secondary steroid resistance in asthma may arise in response to the release of cytokines that activate AP-1 and other transcription factors that bind directly to GR. A similar effect may also be seen with high concentrations of β_2-agonists that activate another GR binding transcription factor, CREB. Several existing and novel treatment strategies are possible in the management of SR asthma.
机译:对糖皮质激素在哮喘和其他炎性和免疫性疾病中抗炎作用的耐药性并不常见,但存在管理问题。了解类固醇抵抗的机制为类固醇的作用机制以及潜在的慢性疾病过程提供了新的见解。在患有原发性类固醇耐药性(SR)的哮喘患者中,外源性类固醇的药代动力学没有异常,并且类固醇与糖皮质激素受体(GR)的结合没有明显的缺陷。最近的研究表明,GR与DNA的结合显着减少。这似乎是由于GR与转录因子激活蛋白1(AP-1)的结合增加所致。哮喘的继发性类固醇耐药性可能是由于激活AP-1的细胞因子释放以及直接结合GR的其他转录因子而引起的。用高浓度的β_2激动剂激活另一种GR结合转录因子CREB,也可以看到类似的效果。在SR哮喘的治疗中,几种现有的和新颖的治疗策略是可能的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号